AN2 Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
AN2 Therapeutics, Inc. (ANTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.60 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Compensation Related Costs
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2022-08-11
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-06-30 was $1.40M.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $200.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month |
|---|---|---|
| 2022-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.60M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $200.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |